Market Performance - The North Exchange 50 Index saw a weekly increase of +0.58% from February 9 to February 13, 2026[3] - The average daily trading volume on the North Exchange was approximately CNY 18.575 billion, with a total trading volume of CNY 92.876 billion and a turnover rate of 16.85% during the same period[4][5] - The overall price-to-earnings (P/E) ratio for the North Exchange was approximately 46.94 times, which is higher than the ChiNext's 45.74 times but lower than the Sci-Tech Innovation Board's 78.61 times[21] Sector Performance - Among the 294 listed companies on the North Exchange, 103 companies had positive weekly growth, with the highest being Aide Technology (+144.72%) and Haiseng Medical (+133.86%)[10] - The media sector experienced a significant increase of +22.6%, while the oil and petrochemical sector saw a decline of -8.7%[10] Financing and Regulatory Measures - The North Exchange introduced a comprehensive package of measures to optimize refinancing, focusing on supporting quality listed companies and innovative small and medium-sized enterprises[40] - Key measures include improving the review process for quality companies, enhancing inclusivity for innovative SMEs, simplifying disclosure requirements, and strengthening regulatory oversight[41] Investment Strategy - The recommended investment strategy for 2026 emphasizes focusing on new productive forces in sectors such as renewable energy, intelligent manufacturing, and emerging consumption industries[27] - A bottom-up approach based on financial metrics is advised, targeting companies with high growth potential and strong R&D investment[27] Risk Factors - Potential risks include lower-than-expected policy support, rapid technological changes, and intensified market competition[3]

Group 1: Linping Development (603284) - Linping Development focuses on the research, production, and sales of corrugated paper and boxboard products, recognized as a high-tech enterprise with independent R&D capabilities [2] - The company is controlled by Li Jianshe, who holds 84.86% of the shares directly and an additional 3.54% indirectly, totaling 88.40% of the voting rights [2] - The total funds raised by Linping Development amount to 714.18 million yuan, with a net amount of 624.09 million yuan allocated for projects including the annual production of 900,000 tons of green intelligent manufacturing new materials [2] Group 2: Electric Science Blue Sky (688818) - Electric Science Blue Sky specializes in the R&D, production, sales, and services of electric energy products and systems, covering applications from deep sea to deep space [3] - The company is primarily controlled by China Electronics Technology Group Corporation, which holds 48.97% of the shares directly and additional indirect holdings, resulting in a total control of 84.50% of the voting rights [3] - The total funds raised by Electric Science Blue Sky are 1.64 billion yuan, with a net amount of 1.58 billion yuan designated for the industrialization of aerospace power systems [4] Group 3: Aide Technology (920180) - Aide Technology is engaged in the R&D, production, and sales of orthopedic medical devices, focusing on products such as spinal, trauma, and sports medicine consumables [5] - The company is controlled by Lu Qiang and Huang Meiyu, who together hold 79.07% of the shares before the issuance, with a reduction to 59.30% post-issuance [5] - The total funds raised by Aide Technology amount to 226.50 million yuan, with a net amount of 196.99 million yuan allocated for projects including the expansion of orthopedic consumables production and the establishment of a research center [5]

Group 1: Core Views - The article highlights the recent surge in A-share market, particularly the significant rise of Hengyun Chang, which saw a peak increase of over 320% on its debut, yielding nearly 150,000 yuan per share [1][6] - This week, two new stocks are available for subscription: Yisiwei and Aide Technology, with Yisiwei being a leader in automotive manufacturing machine vision equipment and Aide Technology focusing on orthopedic medical devices [1][4] Group 2: Yisiwei Overview - Yisiwei's offering price is set at 55.95 yuan per share, with a maximum subscription limit of 6,000 shares per account, requiring a market value of 60,000 yuan in the Shanghai market for full subscription [1] - The company has developed over ten products for various automotive manufacturing processes, achieving a market share of 22.5% in China's automotive machine vision sector by 2024, surpassing foreign competitors [2] - Yisiwei's revenue projections for 2022 to 2024 are 223 million yuan, 355 million yuan, and 392 million yuan, respectively, with net profits of 6.12 million yuan, 61.06 million yuan, and 85.64 million yuan [2] Group 3: Aide Technology Overview - Aide Technology's offering price is 7.67 yuan per share, with a maximum subscription limit of 1.3288 million shares [4] - The company specializes in orthopedic medical devices, focusing on a comprehensive range of products for spinal, trauma, and sports medicine, and has developed several core technologies [4] - Revenue forecasts for Aide Technology from 2022 to 2024 are 286 million yuan, 262 million yuan, and 275 million yuan, with net profits of 93 million yuan, 64 million yuan, and 67 million yuan [4]

Group 1: Company Overview - Yisiwei's IPO price is set at 7.67 CNY per share, focusing on machine vision equipment for the automotive manufacturing sector, providing solutions across various manufacturing processes [1] - The company is projected to achieve a market share of 13.7% in China's automotive manufacturing machine vision market and 22.5% in the overall automotive manufacturing sector by 2024, leading the industry [1] - Yisiwei has developed over ten products, covering six major manufacturing processes, establishing a comprehensive product range and application advantage, serving most domestic automotive manufacturers [1] Group 2: Business Growth and Financial Performance - From 2022 to 2024, Yisiwei's revenue is expected to grow from 22.3 million CNY to 39.2 million CNY, with a compound annual growth rate (CAGR) of 32.59%, while net profit is projected to increase from 5.39 million CNY to 84.43 million CNY, with a CAGR of 295.66% [2] - Aide Technology's IPO price is set at 55.95 CNY per share, focusing on orthopedic medical devices, including spinal, trauma, and sports medicine products [2] - The total fundraising amount for Aide Technology is 197.02 million CNY, aimed at expanding orthopedic consumables production, building a research center, and developing a marketing network [2] Group 3: Market Trends - The market size for orthopedic implant medical devices in China is expected to grow from 19.3 billion CNY in 2016 to 24.6 billion CNY by 2024, with a CAGR of 3.08%, despite a recent market contraction due to procurement policies [2] - Specific segments, such as the sports medicine market, continue to show growth despite overall market challenges [2]

Group 1: Company Overview - Yisiwei is a leading domestic company in automotive manufacturing machine vision equipment, holding the largest market share in China [2] - Aide Technology specializes in orthopedic consumables, focusing on the research, production, and sales of medical devices [3] Group 2: Financial Performance - Yisiwei's projected revenues for 2022 to 2024 are 223 million, 355 million, and 392 million yuan, with net profits of 6 million, 61 million, and 86 million yuan respectively [2] - Aide Technology's projected revenues from 2022 to 2025 are 286 million, 262 million, 275 million, and 302 million yuan, with net profits of 93 million, 64 million, 67 million, and 78 million yuan respectively [3] Group 3: Market Position and Growth Potential - Yisiwei's products are widely used by mainstream joint ventures, domestic new forces, and well-known automotive parts companies, indicating strong market penetration [2] - Aide Technology ranks third in the domestic market for spinal vertebroplasty systems and sixth for spinal implant medical devices, showcasing its competitive position [3] Group 4: Upcoming IPO Details - Yisiwei's IPO price is set at 55.95 yuan per share with a price-to-earnings ratio of 90.39, while Aide Technology's IPO price is 7.67 yuan per share with a price-to-earnings ratio of 14.98 [1][3]

Core Insights - The recent debut of Dapeng Industrial on the Beijing Stock Exchange (BSE) saw an unprecedented surge, with an intraday high increase of over 16 times and a closing increase of 12.11 times, setting a new record for first-day gains of new stocks on the BSE [1][2] - The BSE new stock market is experiencing a significant uptick, driven by a surge in specialized and innovative enterprises going public, attracting substantial investment interest [1][4] - The pace of IPO approvals on the BSE has accelerated, with three companies passing the review on the same day, indicating a robust supply of new listings [4][6] Company Highlights - Dapeng Industrial is a leading manufacturer of specialized intelligent equipment for industrial precision cleaning, primarily serving the automotive sector, including major clients like BYD, Changan, and Geely [2][5] - The company has received multiple accolades, including being recognized as a national-level "specialized, refined, and innovative" enterprise and a "green factory" by the Ministry of Industry and Information Technology [2] - Other companies recently approved for IPO include Aide Technology, specializing in orthopedic medical devices, Tongling Technology, focusing on automotive interior parts, and Jingqiang Technology, a supplier of electromagnetic wire [5][6] Market Trends - The average first-day gain for new stocks on the BSE has been impressive, with six stocks surpassing a 500% increase, indicating a strong market appetite for new listings [3][4] - Analysts predict a normalization of IPO issuance, estimating around 40 new stocks to be launched by the end of the year, with a focus on high-quality growth companies [1][7] - The current market environment is characterized by a high-quality expansion phase, with a concentration on technology and advanced manufacturing sectors [8]